The group’s principle activity is to provide innovative, research-driven services to pharmaceutical cardiac safety trials. The group also develops and markets novel advanced ECG-based biomarkers, as well as improved methods for measuring standard ECG-based biomarkers in clinical trials. The group’s services include study design consultation with selection of appropriate ECG based endpoints, training, set up, quality control and monitoring of clinical sites, ECG data acquisition and transfer, analysis of ECG signal data in the centralized electrocardiography lab, and reporting to the study sponsor and sites. The group operates from United States.
